News & Topics
Semaphorin 4A improves the efficacy of anti-PD-1 antibody (Kumanogoh G, in Sci Adv.)
Although immune checkpoint inhibitors have brought major advances in cancer treatment, their effectiveness is still far from satisfactory. We need to develop novel biomarkers and therapies that strengthen their effectiveness.
Yujiro Naito, Shohei Koyama, Atsushi Kumanogoh (Graduate School of Medicine, Osaka University/IFReC), and the research group shows that histologically Semaphorin 4A (Sema4A)-positive non-small cell lung cancer (NSCLC) responded significantly better to anti-programmed cell death 1 (PD-1) antibody than Sema4A-negative NSCLC.
Prof. Atsushi Kumanogoh